Valois Pharma expands US manufacturing facility

Valois Pharma, a world leader in nasal and pulmonary drug delivery devices, is increasing production capacity at its US facility at Congers, New York.

The scale-up is expected to be completed by 2011 and will create around 30 new jobs.

There are two main stages in the manufacture of nasal spray drug delivery devices (nasal pumps): precision injection moulding of plastic components and high-speed assembly of components and sub-assemblies. Until now, nasal pump components manufactured at the Congers site were moulded in Europe and assembled at Congers. However, moulding is now being integrated into the New York site's manufacturing process, upstream of assembly. The company says the move will allow it better to meet the expectations of its North American clients.

The initial phase of the project, which started at the end of 2008 and will be completed at the end of 2009, includes the creation of a moulding workshop, the construction of a new ISO 7 cleanroom, and the acquisition of injection presses. The second phase of the project will see installation of additional manufacturing capacity to cope with expected market growth.

The expansion at Congers is part of Valois Pharma's international strategy to continuously develop and modernise its four manufacturing facilities at Congers, Le Vaudreuil (France), Lugano (Switzerland) and Suzhou (China).